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Abstract 
Background: The MRZ reaction (MRZR), composed of the three antibody indices (AI) against measles, rubella and 
varicella zoster virus and found positive in the majority of relapsing-remitting multiple sclerosis (RRMS) patients, is 
absent in other inflammatory neurological diseases (OIND). So far, it has been uncertain whether its differential diag-
nostic promise extends to patients with primary-progressive multiple sclerosis (PPMS).
Objective: To investigate the prevalence of MRZR in PPMS compared to RRMS and OIND patients.
Methods: MRZR was assessed in patients with PPMS (n = 103), RRMS (n = 100) and OIND (n = 48). Both stringency 
levels for MRZR testing, MRZR-1 (≥1 AI positive) and MRZR-2 (≥2 AI positive), were applied.
Results: Prevalence of positive MRZR-1 was 83.5% in PPMS and 67.8% in RRMS (p < 0.05). A positive MRZR-2 was 
found in 54.4% of PPMS and in 43.0% of RRMS patients (not significant). Compared to both MS subgroups, OIND 
patients exhibit lower frequencies of positive MRZR (MRZR-1: 22.9%, MRZR-2: 8.3%; p < 0.0001 each).
Conclusion: Positive MRZR was at least as frequent in PPMS as in RRMS and much less frequent in OIND, confirming 
its promise as a potentially useful diagnostic tool for distinguishing both MS course types from OIND.
Keywords: Primary progressive multiple sclerosis, PPMS, Intrathecal polyspecific antiviral immune response, MRZ 
reaction, MRZR, Oligoclonal bands, OCB
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Background
Multiple sclerosis (MS) is a chronic inflammatory auto-
immune central nervous system (CNS) disorder dis-
playing a variable disease course. At clinical onset, 
more than 85% of MS patients are classified as having 
relapsing-remitting MS (RRMS) [1]. These patients are 
predominately female and typically 20–30  years old at 
presentation of initial symptoms [1]. The remaining 
10–15% of MS patients exhibit primary progressive MS 
(PPMS), characterised by a continuous worsening of 
symptoms from the onset, when patients are typically 
between 30 and 50 years old [1, 2]. PPMS affects men and 
women with similar frequency [1]. Both types of disease 
course exhibit inflammatory changes in the cerebrospinal 
fluid (CSF), e.g. the presence of oligoclonal bands (OCB), 
and inflammatory lesions in CNS detectable by magnetic 
resonance imaging (MRI) [1–3]. Diagnosis of PPMS and 
RRMS across the world today widely follows the 2010 
revision of the McDonald criteria [4]. These require for 
PPMS a continuous disease progression of more than 
one year and that at least two of three additional criteria 
are met, one which is the presence of OCB in CSF. CSF 
analysis is no longer crucial for RRMS diagnosis, as here 
McDonald criteria primarily rely on clinical and MRI 
findings [4]. Despite their above mentioned similarities 
it is still a matter of debate whether PPMS and RRMS 
share sufficient underlying pathophysiological character-
istics to be regarded as phenotypes of the same disorder 
and accordingly it cannot be taken as given that both will 
exhibit the MRZ reaction (MRZR) with similar frequency 
[3].
MRZR, first described in 1992, is a polyspecific, 
intrathecal humoral immune response to the three most 
frequent neurotropic viruses found in many RRMS 
patients: measles (M), rubella (R) and varicella zoster (Z), 
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assessed using the three respective antibody indices (AI) 
[5]. A positive AI usually indicates intrathecal synthesis 
of antibodies against the respective pathogen, which is or 
recently was present in patient CSF. The absence of virus 
DNA in the CSF of MS patients with positive MRZ-AI 
led to the hypothesis of a ‘bystander reaction’, described 
as polyspecific B cell activation within the CNS [6]. While 
the pathophysiological role of MRZR may require further 
research, the interest in clinical practice is its potential 
to contribute to alternative diagnosis of MS. Whereas a 
positive MRZR is found in many RRMS patients, a few 
studies have shown negative MRZR in most patients with 
other autoimmune inflammatory neurological diseases 
(OIND) such as neuromyelitis optica (NMO), paraneo-
plastic neurological syndromes (PND), neurosarcoido-
sis (NS), acute disseminated encephalomyelitis (ADEM) 
and autoimmune encephalitis (AIE) [5, 7–9]. Addition-
ally, MRZR has also been shown to be widely negative in 
patients with infectious CNS diseases which can mimic 
MS, such as Lyme neuroborreliosis and HTLV-I associ-
ated myelopathy [10, 11].
Studies showing a high prevalence of positive MRZR in 
MS to date are certainly fully applicable to RRMS; how-
ever the proportion of PPMS patients studied has been 
small, where any were included. Given current uncer-
tainty about the similarity of PPMS and RRMS patho-
physiology, and lack of understanding of the mechanisms 
linking MRZR to MS, our specific aim was to investigate 
MRZR in patients with PPMS.
Another limitation of previous studies has been the 
use of different criteria for positive MRZR. Some studies 
required only a single positive AI to constitute positive 
MRZR (MRZR-1), concluding that the prevalence of pos-
itive MRZR in MS is up to more than 90% [5], whereas 
others have required at least two AI positives for positive 
MRZR (MRZR-2), resulting in estimates of prevalence in 
MS of even below 50% [12].
This study investigated the prevalence of MRZR indi-
cated by both the laxer MRZR-1 and the stricter MRZR-2 
in a large cohort of PPMS patients. Results were com-
pared to the prevalence of MRZR among patients with 
RRMS and some OIND.
Methods
Patients
This is a retrospective study in which all patients were 
treated at the University Medical Centre Freiburg in Ger-
many between 2003 and 2015. Lumbar puncture (LP) 
had already been performed for all patients—for clinical 
purposes only and after written consent. CSF and serum 
samples were taken on the same day and stored according 
to consensus protocol for the standardization of CSF col-
lection and biobanking [13]. Haemolytic CSF specimens 
were excluded. Diagnosis of MS was established accord-
ing to the 2010 revised McDonald criteria, with particu-
larly careful exclusion of relevant differential diagnoses 
[4]. All PPMS patients in the MS cohort were included 
for whom an MRZR measurement had been recorded 
or could be performed with existing CSF and serum 
samples. The MS cohort was screened for those with a 
recorded MRZR result, and from this set of MS patients, 
100 RRMS patients were randomly drawn. The OIND 
group consisted of 48 patients for whom MRZR results 
were available from previous research, and unlike MS 
groups the OIND group did not include patients treated 
in 2015 [9]. Data concerning the ethnicity and immu-
nization status of study patients was not available. The 
ethics committee of University Medical Centre Freiburg 
approved the study.
MRZR and CSF analysis
All MRZR assessments were performed at the Depart-
ment of Virology of the University of Freiburg between 
2003 and 2015. All other CSF measurements relevant to 
this study were carried out in the CSF laboratory at the 
Department of Neurology. The CSF laboratory at the 
Department of Neurology regularly takes part in the 
External Quality Control of Diagnostic Assays and Tests 
(EQAS) for CSF diagnostics, including protein analytics, 
and the laboratory at the Department of Virology regu-
larly takes part in the EQAS for virus diagnostics, includ-
ing virus serology. Both EQAS procedures are performed 
by Instand e.V. (Gesellschaft zur Förderung der Qual-
itätssicherung in medizinischen Laboratorien e.V.; Düs-
seldorf; Germany).
Total immunoglobulin (Ig) concentrations in serum 
and CSF were detected nephelometrically (ProSpect 
System, Siemens, Germany), whereas measles-, rubella- 
and varicella-IgG (IgGspec) levels in CSF and serum 
were measured by enzyme linked immunosorbent 
assay (Serion classic ELISA, Germany), both accord-
ing to the manufacturer’s instructions. MRZR was 
determined from the three respective virus-specific 
AI which were calculated as follows: AI  =  QIgG[spec]/
QIgG[total], if QIgG[total] < Qlim, and AI = QIgG[spec]/Qlim, if 
QIgG[total] > Qlim according to Reiber’s formula [14]. For a 
positive AI finding the threshold of AI ≥ 1.5 was applied 
[9, 10, 12, 15]. Previous studies have varied as to how 
many positive AIs are required for positive MRZR. In 
this study, MRZR-2 is used to refer to the MRZR defi-
nition requiring two or more positive AI, and MRZR-1 
to refer to the MRZR definition requiring only one or 
more positive AI. Where an AI could not be calculated 
because no antibodies were detected in the CSF, AI was 
considered to be 1.0 (negative). CSF laboratory records 
were used which routinely include total CSF cell count, 
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significant quantitative intrathecal antibody synthesis 
(defined as ≥10%), IgG index, QIgG, IgG concentration 
in CSF and presence or absence of oligoclonal bands 
(OCB) according to the Reibergrams and the CSF con-
sensus report [16]. Detection of OCB for patients was 
performed using a highly sensitive isoelectric focusing 
technique on agarose gel followed by immunofixation 
(Hydragel Isofocusing, sebia, France) [17]. A positive 
OCB finding is defined as two or more OCB [16].
Statistical analysis
Statistical testing of differences between groups on gen-
der, prevalence of positive AI, MRZR, intrathecal Ig syn-
thesis and OCB was performed using Fisher’s exact test 
(two-tailed). Differences of mean values of AI, total CSF 
cell count, intrathecal Ig synthesis, QIgG, IgG concentra-
tions in CSF and age between groups were tested using 
Student’s t test (two-tailed). A p value <0.05 was regarded 
as statistically significant. The correlation between 
MRZR and OCB status was measured using the Phi cor-
relation coefficient (φ). A correlation coefficient between 
0.2 and 0.4 was considered as weak, between 0.4 and 0.6 
as intermediate and >0.6 as strong.
Results
Study population
The complete 2003–2015 cohort consisting of 1668 
patients with a recorded MS diagnosis was retrospec-
tively screened for MS subtype, RRMS or PPMS, follow-
ing the 2010 McDonald criteria [4]. 236 PPMS patients 
(14.1%) were found of whom 96 had to be excluded due 
to missing CSF/serum samples and 37 due to insufficient 
clinical data, resulting in a PPMS group of 103 well-
characterized patients. A random sample of 100 RRMS 
patients already tested for MRZR for clinical reasons was 
drawn from the same MS cohort. Additionally, an exist-
ing group of 48 patients with OIND was drawn on for 
comparison. Twenty-two of this OIND group had been 
diagnosed with neurosarcoidosis (NS), 19 with autoim-
mune encephalitis (AIE) and 7 with acute disseminated 
encephalomyelitis (ADEM). Table  1 shows key demo-
graphic features of the three study groups.
Virus‑specific antibody indices (AI)
Results of AI tests of the three study groups are shown in 
Table 2. No statistically significant differences were found 
between the two MS groups in respect of frequency of 
one, two or three positive AIs and mean values of any 
of the three AI (M, R and Z). However, a positive AI for 
M and R was statistically significantly more frequent in 
PPMS compared to RRMS. Compared to both MS sub-
groups, the OIND group showed lower mean AI values 
and less frequent positive AI for all three viruses.
MRZR
In accordance with AI findings, positive MRZR was 
found in a minority of OIND patients (MRZR-2: 8.3%, 
MRZR-1: 22.9%), statistically significantly less than in 
either of the MS subtypes (PPMS MRZR-2: 54.4%, PPMS 
MRZR-1: 83.5%; RRMS MRZR-2: 43.0%, RRMS MRZR-1: 
69.0%—see Fig. 1).
Merging the two MS subtypes (PPMS and RRMS, 
n  =  203) confirms that frequencies of both positive 
MRZR-2 (48.8%) and MRZR-1 (76.4%) among MS 
patients are statistically significantly different to those 
found in the OIND group (p < 0.0001 each).
Comparison of MRZR results with previous studies
Table  3 presents MRZR results from the present study 
alongside those from previous studies. For these stud-
ies, findings from both MRZR definitions (MRZR-2 and 
MRZR-1) are listed where these could be reconstructed 
from the data provided in the relevant publication.
OCB
As can be seen from Fig.  2, the prevalence of positive 
OCB in CSF was similar in the two MS groups (93.2% for 
PPMS and 87.0% for RRMS) and significantly higher than 
in the OIND group (31.2%).
OCB and MRZR
As presented in Tables 4 and 5, there was a weakly posi-
tive correlation between OCB and MRZR status (apply-
ing to both MRZR-2 and MRZR-1) in the combined 
MS group. Among the few OCB negative MS patients, 
Table 1 Demographic data of all study patients
PPMS primary progressive multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, OIND other autoimmune inflammatory neurological diseases comprising 
22 patients with neurosarcoidosis (NS), 19 with autoimmune encephalitis (AIE) and 7 with acute disseminated encephalomyelitis (ADEM), n number of patients, LP 
lumbar puncture, SD standard deviation, n.s. not significant
Study group PPMS (n = 103) RRMS (n = 100) OIND (n = 48) Comparison statistics
Gender, females in % 60.2 73.0 41.7 p < 0.05 for both MS groups vs. OIND; between MS 
groups: n.s.
Mean age in years at LP (range; SD) 51.3 (25–78; 10.0) 40.0 (19–74; 11.3) 51.8 (4–84; 18.4) p < 0.0001 for PPMS and OIND vs. RRMS; between PPMS 
and OIND: n.s.
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15.0 and 30.0% showed positive MRZR-2 and MRZR-1 
respectively.
CSF routine findings in MS patients
Inflammatory CSF changes were found in 93.2% of PPMS 
patients and in 87% of RRMS patients (n.s.). The most 
frequent pathological CSF finding was positive OCB (see 
above) followed by quantitative intrathecal IgG synthesis 
(51.5% in PPMS patients and 50.0% in RRMS; n.s.), ele-
vated total CSF cell count (PPMS: 22.3%, RRMS: 43.0%; 
p < 0.01), quantitative intrathecal IgM synthesis (PPMS: 
8.7%, RRMS: 14.8%; n.s.) and quantitative intrathecal IgA 
synthesis (PPMS: 7.8%, RRMS: 8.0%; n.s.). The data from 
the routine CSF analyses are presented in Table 6.
Discussion
To our knowledge, this is the first systematic investiga-
tion of the MRZR in a distinct PPMS cohort of reason-
able size, and comparison with RRMS and OIND. The 
two main results are that positive MRZR is at least as 
frequent in PPMS as in RRMS patients and significantly 
more frequent than among OIND patients.
Study population
PPMS patients showed typical demographic features: a 
more balanced gender distribution and a higher average 
age than RRMS patients [3, 18]. It has to be mentioned 
that diagnosis of RRMS can usually now be made earlier 
than at the mean age of this cohort (39 years). The high 
Table 2 Antibody indexes for all study patients
PPMS primary progressive multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, OIND other autoimmune inflammatory neurological diseases, positive AI 
antibody index for measles (M), rubella (R) or varicella zoster (Z) ≥1.5, n.s. not significant
PPMS (n = 103) RRMS (n = 100) OIND (n = 48) Comparison statistics
Patients with 0 positive AI 16.5% 31.0% 77.1% p < 0.0001 for both MS groups vs. OIND; p < 0.05 between MS 
groups
Patients with 1 positive AI 29.1% 26.0% 14.6% all comparisons: n.s.
Patients with 2 positive AI 25.2% 25.0% 6.3% p < 0.01 for both MS groups vs. OIND; between MS groups: n.s.
Patients with 3 positive AI 29.1% 18.0% 2.1% p < 0.01 for both MS groups vs. OIND; between MS groups: n.s.
Positive AI for M 62.1% 48.0% 6.3% p < 0.001 for both MS groups vs. OIND; p < 0.05 between MS 
groups
Positive AI for R 57.3% 43.0% 12.5% p < 0.001 for both MS groups vs. OIND; p < 0.05 between MS 
groups
Positive AI for Z 48.5% 39.0% 14.6% p < 0.05 for both MS groups vs. OIND; between MS groups: n.s.
Mean AI for M (range; SD) 3.3 (0.8–20.3; 3.2) 3.2 (0.6–52.2; 6.3) 1.0 (0.6–2.6; 0.3) p < 0.01 for both MS groups vs. OIND; between MS groups: n.s.
Mean AI for R (range; SD) 3.1 (0.5–24.0; 4.0) 3.0 (0.5–19.8; 4.0) 1.2 (0.6-8.3; 1.2) p < 0.01 for both MS groups vs. OIND; between MS groups: n.s.
Mean AI for Z (range; SD) 3.0 (0.6–19.8; 3.7) 2.5 (0.6–25.4; 3.5) 1.2 (0.4–3.8; 0.6) p < 0.05 for both MS groups vs. OIND; between MS groups: n.s.
Fig. 1 Frequency of positive MRZR-2 and MRZR-1 in patients with PPMS, RRMS and OIND. Frequency of positive MRZR-2 and MRZR-1 in patients 
with primary progressive multiple sclerosis (PPMS), relapsing-remitting multiple sclerosis (RRMS) and other autoimmune inflammatory neurological 
diseases (OIND). MRZR-2 one or more positive AI, MRZR-1 two or more positive AI, n.s. not significant
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average age of RRMS patients might be a consequence of 
selection bias, as discussed below.
AI and MRZR
Frequencies of positive AI and AI mean values in both 
MS groups (M > R > Z) were similar compared to a pre-
vious study but inverse in OIND patients (M  <  R  <  Z, 
Table  2) [15]. The rather low frequency of positive 
MRZR-2 in the OIND group indicates that MRZR-2 
might be particularly helpful in distinguishing both 
MS subtypes from OIND. The less rigorous MRZR-1 is 
clearly less specific, showing more false positive results in 
OIND. This was also found in another recent study in ter-
tiary care, where MRZ-1 was found to be positive in 19% 
of patients with OIND (well in line with the 23% in our 
OIND group) and 8% of patients with other non-inflam-
matory neurological diseases (OND), whereas none of 
these 53 patients were MRZR-2 positive [19]. Up to now, 
there is no indication of a pathophysiological role of any 
of the three MRZ viruses in MS pathogenesis, unlike in 
the case of the Epstein-Barr-virus (EBV) where it was 
shown that after EBV infection the risk of developing MS 
is increased [20].
Table  3 illustrates how inconsistent results of MRZR 
studies can appear if differences in definition (MRZR-2 
vs. MRZR-1) are not considered. After clearly distin-
guishing between MRZR-2 and MRZR-1, the MRZR 
results from this study align quite well with most previ-
ous research. The study shows positive MRZR-1 in 76% 
of MS patients, which is less frequent than in some ear-
lier studies [5, 10, 15, 21]. But, the frequency of positive 
MRZR-1 is closely in line with two other recent studies 
[22, 23]. Furthermore, several studies established a simi-
lar frequency of MRZR-2 positives of around 50% [10, 12, 
21, 22, 24]. Exceptionally, Jarius et al. reported a consid-
erably higher proportion of positive MRZR-2 (88%) in 
their MS cohort, which was used in two MRZR studies 
Table 3 A comparison of MRZR studies in multiple sclerosis patients
The studies are presented in descending order of number of patients
Numbers in brackets were calculated by the author from data available in the respective article where possible
MRZR-1 one or more positive antibody indices (AI) for measles (M), rubella (R) and varicella zoster (Z), MRZR-2 two or more positive AI, CIS clinical isolated syndrome, 
SPMS secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, n.a. not available
a This study investigated only OCB-negative MS patients
b This study included AI for HSV
Study Number of MS patients (MS subtypes) Positive MRZR‑2 Positive MRZR‑1
Present study n = 203 (PPMS: n = 103, RRMS: n = 100) 49% 76%
Reiber et al. [15] n = 177 (no data concerning subtype) [67%] 89%
Felgenhauer et al. [5] n = 100 (no data concerning subtype) [72%] 94%
Rosche et al. [24] n = 68 (RRMS: n = 61, CIS: n = 7) 58% [n.a.]
Brettschneider et al. [12] n = 49 (CIS patients who converted to MS within 2 years) 47% [n.a.]
Brecht et al.a [19] n = 46 (RRMS: n = 26, SPMS: n = 12, PPMS: n = 8) [24%] 46%
Jarius et al. [7] n = 42 (RRMS: n = 29, SPMS: n = 4, CIS: n = 9) 88% [n.a.]
Bednarova et al. [10] n = 42 (no data concerning subtype) [47%] 88%
Hottenrott et al. [9] n = 33 (RRMS: n = 14, SPMS: n = 5, PPMS: n = 14) 70% [82%]
Kulakowska et al.b [22] n = 27 (RRMS: n = 21, PPMS: n = 6) [56%] 81%
Tumani et al. [23] n = 26 (no data concerning subtype) [n.a.] 73%
Robinson-Agramonte et al. [21] n = 23 (incomplete data concerning subtype) [48%] 100%
Fig. 2 Prevalence of OCB in CSF of patients with PPMS, RRMS and 
OIND. Prevalence of oligoclonal bands (OCB) in cerebrospinal fluid 
(CSF) of patients with primary progressive multiple sclerosis (PPMS), 
relapsing-remitting multiple sclerosis (RRMS) and other autoimmune 
inflammatory neurological diseases (OIND), n.s. not significant
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[7, 8]. Reasons for this divergence remain elusive, but 
selection bias is a conceivable explanation. Unfortunately, 
study reports did not include a detailed description of 
patient selection. In the present study, there may have 
been selection bias in the RRMS group, due to includ-
ing patients with MRZR already previously performed 
for clinical reasons. Though such a bias might have con-
tributed to their unexpectedly high mean age, this was 
actually similar to the mean age of MS patients in an even 
larger retrospective CSF study (not addressing MRZR) 
[25]. There is a lower risk of selection bias in the PPMS 
group because all available PPMS patients were included 
in the analysis, where possible. This is supported by the 
fact that our PPMS group matches demographic charac-
teristics of PPMS patients studied elsewhere very well [1, 
3, 18]. Limitations of this study include the monocenter 
cohort, the retrospective design and the lack of data 
concerning ethnicity and vaccination status of enrolled 
patients. Infection rates and vaccination status in respect 
of the three MRZ viruses can influence MRZR results, as 
has been demonstrated for the rubella virus in Cuba [21]. 
Therefore, verification of the MRZR results for PPMS 
patients with known vaccination status, and expansion 
to a multicenter prospective study, including populations 
from different parts of the world, would be a valuable 
next step.
OCB and other CSF routine parameters
As expected, a high and very similar prevalence of OCB 
of around 90% was found in PPMS and RRMS patients- 
confirming the high sensitivity of this CSF parameter for 
both MS subgroups. The prevalence of OCB in PPMS 
and RRMS patients found here matches the findings of a 
previous monocenter Canadian study investigating 451 
MS patients with CSF analyses performed between 1993 
and 2007 [25]. In that study positive OCB was reported 
in 91% of RRMS and in 85% of PPMS patients.
Though the high prevalence of OCB in MS patients 
can be useful, a diagnostic disadvantage of OCB is their 
high prevalence in related conditions of diagnostic 
importance, in particular OIND. For example, OCB can 
be found in 40% of patients with neurosarcoidosis and 
in 50% of patients with neurologic complications of sys-
temic lupus erythematosus (neuro-SLE) [9, 26].
The correlation between MRZR and OCB positivity 
in MS patients was weak, showing that MRZR provides 
additional, independent diagnostic information as previ-
ously reported for clinical isolated syndrome (CIS) [12]. 
One important issue in this context is whether MRZR 
tests can potentially improve the accuracy of diagno-
sis based on the 2010 revised McDonald criteria [4]. 
Table 4 Correlation between  the presence of  oligoclonal 
bands and MRZR-2 in patients with multiple sclerosis
OCB positive ≥2 oligoclonal bands in CSF, MRZR-1 one or more positive 
antibody indices (AI) for measles (M), rubella (R) and varicella zoster (Z), MRZR-2 
two or more positive AI, positive AI AI ≥ 1.5, combined MS group: all primary 
progressive multiple sclerosis patients (n = 103) and relapsing-remitting 




OCB positive OCB negative Association 
metrics




183 20 203 ф = 0.22
Table 5 Correlation between  the presence of  oligoclonal 
bands and MRZR-1 in patients with multiple sclerosis
OCB positive ≥2 oligoclonal bands in CSF, MRZR-1 one or more positive 
antibody indices (AI) for measles (M), rubella (R) and varicella zoster (Z), MRZR-2 
two or more positive AI, positive AI AI ≥ 1.5, combined MS group: all primary 
progressive multiple sclerosis patients (n = 103) and relapsing-remitting 




OCB positive OCB negative Association 
metrics




183 20 203 φ = 0.36
Table 6 Results of routine CSF analysis for MS patients
PPMS primary progressive multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, IgG immunoglobuline G, IgA immunoglobuline A, IgM immunoglobuline M, 
QIgG quotient of IgG, SD standard deviation, n.s not significant. All group values are expressed as means
PPMS (n = 103) RRMS (n = 100) Comparison statistics
Total CSF cell count in/µl (range; SD) 4.1 (1–43; 5.9) 8.9 (1–47; 10.3) p < 0.001
Intrathecal IgG synthesis in % (range; SD) 19.8 (0–75.4; 21.8) 21.6 (0–84.3; 25.0) n.s.
Intrathecal IgA synthesis in % (range; SD) 3.8 (0–54.9; 12.6) 2.1 (0–47.4; 7.5) n.s.
Intrathecal IgM synthesis in % (range; SD) 5.0 (0–92.4; 17.0) 6.1 (0–88.3; 16.8) n.s.
IgG index (range; SD) 0.93 (0.45–2.83; 0.42) 1.02 (0.23–4.0; 0.65) n.s.
QIgG × 10−3 (range; SD) 5.3 (2.0–16.9; 3.1) 5.2 (1.0–15.8; 3.3) n.s.
IgG concentration in CSF in mg/l (range; SD) 60.7 (19.4–217.0; 42.4) 55.9 (9.1–206.0; 39.8) n.s.
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Referring to Tables  4 and 5, it appears that a combina-
tion of MRZR and OCB criteria could extend diagnostic 
sensitivity for the small proportion of OCB negative MS 
patients with 15% MRZR-2 positive and 30% MRZR-1 
positive results. This seemingly contradicts findings in a 
group of 177 MS patients in which no patient was found 
MRZR positive and OCB negative [15]. This led the 
authors to recommend testing for MRZR only in OCB 
positive patients. However, the very high OCB prevalence 
in that study group (98%) meant that there were only three 
or four OCB negative patients, so that it could easily be 
a result of chance that none of these patients were found 
MRZR positive. MRZR/OCB findings of the present study 
are in line with a recent study in which MRZR-2 positives 
made up even 24% of 46 OCB negative MS patients [19]. 
Apart from that, MRZ-specific OCB were found in nearly 
50% of MS patients without routine OCB [17]. Taking 
these results together, testing for MRZR in OCB negative 
patients with suspected MS appears well justified.
Considering the other CSF routine parameters, only the 
total cell count differed between the two MS subgroups: 
RRMS patients more often showed an elevated total cell 
count and a higher mean total cell count compared to 
PPMS patients. All Ig parameters (total IgG concentra-
tion in CSF, QIgG and intrathecal IgG/M/A synthesis) 
were similar between PPMS and RRMS patients parallel-
ing the MRZR-2 results and indicating that these two MS 
subgroups seemingly display similar humoral immune 
responses in CSF.
Conclusions
Positive MRZR has now been shown to be at least as fre-
quent in PPMS patients as in RRMS, suggesting MRZR 
could be used in the diagnostic workup for both subtypes 
of MS in a similar way. MRZR has also been found to be 
less prevalent in OIND patients compared to OCB indi-
cating that particularly the stricter MRZR-2 measure may 
well be helpful in the critical task of distinguishing OIND 
from MS. Altogether, these study results further support 
the significance of CSF analysis as an important tool to 
ensure alternative diagnoses of MS are promptly detected 
and properly treated [27].
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